

dTAGV-1 biochemical

dTAGV-1

CATALOG #
AAA227119


PRODUCT SYNONYMS

dTAGV-1; dTAGV-1 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
Solubility	DMSO: 136.16 mg/mL(100 mM) <1mg/ml refers to the product slightly soluble or insoluble
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Ald-Ph-amido-PEG11-NH-Boc, CAS 1245813-70-0



Structure
Ald-Ph-amido-PEG11-NH-Boc, CAS 1245813-70-0

ADDITIONAL INFORMATION

Related Product Information for dTAGV-1 biochemical	Degrader targeting mutant FKBP12F36V fusion proteins. Comprises a ligand selective for F36V single-point mutated FKBP12, a linker and a von Hippel-Lindau (VHL)-binding ligand. Induces potent and selective degradation of FKBP12F36V fusion proteins in vitro and in vivo. Selectively degrades FKBP12F36V-EWS/FLI fusion proteins and inhibits cell proliferation in FKBP12F36V-EWS/FLI-expressing Ewing sarcoma cells. Hydrochloride salt available; suitable for in vivo use. Negative control dTAGV-1-NEG also available. FKBP12F36V can be expressed as a fusion with a target protein of interest using genome engineering techniques, via transgene expression or CRISPR-mediated locus-specific knock-in. Custom knock-in cell lines for the dTAG and aTAG platforms are available from our sister brand R&D Systems. Email TPD@bio-technie.com to enquire. Plasmid vectors for the lentiviral expression and CRISPR-mediated knock-in of FKBP12F36V are available from Addgene.
References	1. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

